Research Progress of Cytoreductive Treatment for Metastatic Prostate Cancer

Longguo DAI; Yu BAI

doi:10.12259/j.issn.2095-610X.S20230103

Volume 44 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2023 > 44(1): 135-139

Hui-min WAN, Qing ZHOU. Effect of Continuing Motivational Interviewing on the Compliance of Diabetic Cataract Patients after Discharge from Day Surgery[J]. Journal of Kunming Medical University, 2020, 41(11): 165-170. doi: 10.12259/j.issn.2095-610X.S20201114

Citation:

Longguo DAI, Yu BAI. Research Progress of Cytoreductive Treatment for Metastatic Prostate Cancer[J]. Journal of Kunming Medical University, 2023, 44(1): 135-139. doi: 10.12259/j.issn.2095-610X.S20230103

Citation:

PDF( 537 KB)

Research Progress of Cytoreductive Treatment for Metastatic Prostate Cancer

doi: 10.12259/j.issn.2095-610X.S20230103

Longguo DAI,
Yu BAI^,

Dept. of Urinary Surgery，Yunnan Tumor Hospital，Kunming Yunnan 650118，China

Received Date: 2022-11-15
Available Online: 2023-01-18
Publish Date: 2023-01-18

Abstract

Abstract

Metastatic prostate cancer （mPCa） will progress to castrate-resistant state after a period of androgen-deprivation therapy （ADT） alone. Therefore, increasing focus is being placed on the additional survival benefits that could potentially be achieved with local cytoreductive and/or metastasis-directed therapies （MDT）. Local treatment of the primary tumour with the established modalities of radiotherapy and radical prostatectomy has been explored in this context, and the use of novel minimally invasive ablative therapies has been proposed. In addition, evidence of the potential clinical benefits of MDT with ionizing radiation （primarily stereotactic ablative radiotherapy） is accumulating. This aticle summarizes the current evidence base for a cytoreductive strategy in patients with mPCa.
- Metastatic prostate cancer,
- Cytoreductive treatment,
- Ablative therapies,
- Radiotherapy,
- Prostatectomy

FullText(HTML)

References(26)

References

[1]	Siegel R L,Miller K D,Fuchs H E,et al. Cancer statistics,2022[J]. CA Cancer J Clin,2022,72(1):7-33. doi: 10.3322/caac.21708
[2]	Wang L,Paller C J,Hong H,et al. Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: A systematic review and network meta-analysis[J]. JAMA Oncol,2021,7(3):412-420. doi: 10.1001/jamaoncol.2020.6973
[3]	Cheng Q,Butler W,Zhou Y,et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy[J]. Eur Urol,2022,81(5):446-455. doi: 10.1016/j.eururo.2021.12.039
[4]	Ranasinghe W,Chapin B F,Kim I Y,et al. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer[J]. BJU Int,2020,125(6):792-800. doi: 10.1111/bju.15055
[5]	Püllen L,Sprave T,Hadaschik B,et al. [Local and metastasis-directed therapy for oligometastatic prostate cancer][J]. Aktuelle Urol,2021,52(2):149-154. doi: 10.1055/a-1328-9975
[6]	Boevé L M S,Hulshof M,Vis A N,et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial[J]. Eur Urol,2019,75(3):410-418. doi: 10.1016/j.eururo.2018.09.008
[7]	Cho Y,Chang J S,Rha K H,et al. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?[J]. PLoS One,2016,11(1):e0147191. doi: 10.1371/journal.pone.0147191
[8]	Culp S H,Schellhammer P F,Williams M B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study[J]. Eur Urol,2014,65(6):1058-1066. doi: 10.1016/j.eururo.2013.11.012
[9]	Parker C C,James N D,Brawley C D,et al. Radiotherapy to the primary tumour for newly diagnosed,metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial[J]. Lancet,2018,392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3
[10]	Rusthoven C G,Jones B L,Flaig T W,et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer[J]. J Clin Oncol,2016,34(24):2835-2842. doi: 10.1200/JCO.2016.67.4788
[11]	Gratzke C,Engel J,Stief C G. Role of radical prostatectomy in metastatic prostate cancer: Data from the munich cancer registry[J]. Eur Urol,2014,66(3):602-603. doi: 10.1016/j.eururo.2014.04.009
[12]	Sooriakumaran P,Karnes J,Stief C,et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation[J]. Eur Urol,2016,69(5):788-794. doi: 10.1016/j.eururo.2015.05.023
[13]	Jang W S,Kim M S,Jeong W S,et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?[J]. BJU Int,2018,121(2):225-231. doi: 10.1111/bju.13992
[14]	Shemshaki H,Al-mamari S A,Geelani I A,et al. Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: A systematic review and meta-analysis[J]. Urologia,2022,89(1):16-30. doi: 10.1177/03915603211036631
[15]	Lumen N,De Bleser E,Buelens S,et al. The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. Results from the local treatment of metastatic prostate cancer (LoMP) registry[J]. Eur Urol Open Sci,2021,29(6):68-76.
[16]	Heidenreich A,Pfister D,Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: Results of a feasibility and case-control study[J]. J Urol,2015,193(3):832-838. doi: 10.1016/j.juro.2014.09.089
[17]	Shah T T,Peters M,Eldred-evans D,et al. Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry[J]. Eur Urol,2019,76(1):98-105. doi: 10.1016/j.eururo.2018.12.030
[18]	Morkos J,Porosnicu Rodriguez K A,Zhou A,et al. Percutaneous cryoablation for stage 1 renal cell carcinoma: Outcomes from a 10-year prospective study and comparison with matched cohorts from the national cancer database[J]. Radiology,2020,296(2):452-459. doi: 10.1148/radiol.2020192325
[19]	Sheng M X,Wan L L,Liu C M,et al. Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: A retrospective analysis[J]. Kaohsiung J Med Sci,2017,33(12):609-615. doi: 10.1016/j.kjms.2017.07.002
[20]	Reddy D,Peters M,Shah T T,et al. Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: A multi-institute 15-year experience[J]. Eur Urol,2022,81(4):407-413. doi: 10.1016/j.eururo.2022.01.005
[21]	Ishihara H,Takagi T,Kondo T,et al. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era[J]. Urol Oncol,2021,39(1):77.e17-77.e25. doi: 10.1016/j.urolonc.2020.08.011
[22]	Parker C,Nilsson S,Heinrich D,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med,2013,369(3):213-223. doi: 10.1056/NEJMoa1213755
[23]	Ost P,Reynders D,Decaestecker K,et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective,randomized,multicenter phase II trial[J]. J Clin Oncol,2018,36(5):446-453. doi: 10.1200/JCO.2017.75.4853
[24]	O'shaughnessy M J,Mcbride S M,Vargas H A,et al. A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer[J]. Urology,2017,102(4):164-172.
[25]	Radwan N,Phillips R,Ross A,et al. A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE)[J]. BMC Cancer,2017,17(1):453. doi: 10.1186/s12885-017-3455-6
[26]	Sartor O,De Bono J,Chi K N,et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer[J]. N Engl J Med,2021,385(12):1091-1103. doi: 10.1056/NEJMoa2107322

Relative Articles(20)

Relative Articles

[1]	Pingbo XIE, Mingsheng LIU, Hongqing ZHOU, Shaomei WU, Tao SHAO, Feng GUO. Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer. Journal of Kunming Medical University, 2023, 44(12): 46-50. doi: 10.12259/j.issn.2095-610X.S20231208
[2]	Fang WANG, Rong ZHAO, Hong ZHENG. Clinical Effect of Kan Fu Xin Combined with Montmorillonite on the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients with Head and Neck Cancer. Journal of Kunming Medical University, 2021, 42(6): 98-102. doi: 10.12259/j.issn.2095-610X.S20210626
[3]	Jiang ZHANG, Yan LIU, Wen-hui LI, Xi-juan ZHAO, Zheng-ting CHEN, Qiong-yao GUAN, Jiang WU. Effects of Pre-sleep Music Therapy on Sleep Quality and Cancer-related Fatigue in Patients with Breast Cancer Undergoing Radiotherapy. Journal of Kunming Medical University, 2020, 41(12): 173-178. doi: 10.12259/j.issn.2095-610X.S20201248
[4]	Liu Zhong Yi , Hou Jie . . Journal of Kunming Medical University, 2017, 38(03): 107-110.
[5]	Shen Jie , Guan Run Yun , He Zong Hai , Zheng Ming Xing . Comparison of the Efficacy and Complications of PKRP and TmLRP in Treatment of Early Benigh Prostate Hyperplasia. Journal of Kunming Medical University, 2017, 38(06): 77-81.
[6]	Yang Lin Lin . Comparative Study of Concurrent Chemoradiotherapy with Simplex Radiotherapy after Radical Surgery for High-risk Endometrial Cancer. Journal of Kunming Medical University,
[7]	Yang Lin Lin . Clinical Significance of Serum Level of CA125 in Concurrent Chemoradiotherapy for High-risk Endometrial Cancer. Journal of Kunming Medical University,
[8]	Wang Shun Jun . . Journal of Kunming Medical University,
[9]	Zhang Jing Song . . Journal of Kunming Medical University,
[10]	Sun Jian Jun . . Journal of Kunming Medical University,
[11]	Cao Shao Dang . . Journal of Kunming Medical University,
[12]	Ke Kun Bin . . Journal of Kunming Medical University,
[13]	Liu Jin Hong . . Journal of Kunming Medical University,
[14]	Liu Peng Jie . . Journal of Kunming Medical University,
[15]	Niu Hua Tao . . Journal of Kunming Medical University,
[16]	Hu Li Bing . . Journal of Kunming Medical University,
[17]	. . Journal of Kunming Medical University,
[18]	Ruan Dian Sheng . . Journal of Kunming Medical University,
[19]	. . Journal of Kunming Medical University,
[20]	. Clinical Observation of Radiotherapy Combined with Zoledronic Acid in the Treatment of Patients with Bone Metastases Pain. Journal of Kunming Medical University,

Supplements(0)

Cited By

Cited by

Periodical cited type(15)

1.	殷丽. 多形式集体宣教在白内障日间病房手术患者中的应用及对术后健康知识掌握情况的影响. 基层医学论坛. 2024(15): 102-104+144 .
2.	谢驰，陈子盎，章尧，娄炜，金海鹰. 老年性白内障患者血糖与术后视力恢复的关联. 安徽理工大学学报(自然科学版). 2024(02): 94-100 .
3.	付琴，祝青燕，邹霞，黄勇翔，刘悠. 结构化护理干预对老年白内障手术患者自我护理依从性的影响分析. 基层医学论坛. 2024(17): 70-73 .
4.	刘媛，于莹，李景. 延续护理减少老年白内障手术患者术后并发症的效果评价. 中外医疗. 2024(19): 134-137 .
5.	张杨，吕长芬. 延续性护理对2型糖尿病合并老年白内障患者术后的效果评价. 糖尿病新世界. 2024(12): 21-23 .
6.	孙东洋. PDCA循环管理联合延续护理在老年白内障患者中的应用效果. 医药前沿. 2024(27): 95-97 .
7.	徐燕，黄娟，马剑晴. 优质护理结合电话回访在老年白内障日间手术患者中的应用效果. 中西医结合护理(中英文). 2023(02): 21-24 .
8.	朱文娟，赵久华，臧谋红，胡俊，杨丽. 医养结合视角下养老机构中延续护理对糖尿病患者的效果评价. 南通大学学报(医学版). 2023(02): 140-143 .
9.	王瑞，张蓓，孙捷，和心依. 专科护士主导制定的围术期点药单对眼科日间手术患者用药依从性及眼科感染发生率的影响. 海南医学. 2023(12): 1793-1796 .
10.	应莉，黄小建. 基于ADOPT问题解决模式的护理干预在老年性白内障超声乳化术患者中的应用效果. 当代护士(上旬刊). 2023(05): 128-132 .
11.	袁雪，刘嫚. 流程化护理干预在眼科手术患者中的应用效果及对SAS、SDS评分的影响. 临床医学研究与实践. 2023(25): 162-165 .
12.	龙皓，汤宁，应岚. 基于信息-动机-行为技巧模型构建健康教育在中青年慢性精神分裂症患者护理工作中的应用. 心理月刊. 2023(14): 71-74 .
13.	刘民，陈玉春. 基于ADOPT问题解决模式护理干预对玻璃体切割术患者负性情绪、依从性及并发症的影响. 国际护理学杂志. 2023(21): 3903-3907 .
14.	卢仪真. 健康教育联合CICARE沟通模式在眼科日间病房中的应用效果. 医学理论与实践. 2022(03): 505-506 .
15.	张倩. 早期护理干预对缓解老年白内障手术患者术前焦虑的效果分析. 中国医药指南. 2021(30): 118-119 .